ArticleCureus2026
Retrospective Analysis of Oral Tofacitinib Treatment for Alopecia Areata at a Tertiary Care Hospital in Saudi Arabia.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- JAK Inhibitors for Alopecia Areata: Approved Therapies, Efficacy, and Unanswered Questions.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlopecia areata (AA) is a chronic autoimmune disorder characterized by non-scarring hair loss and substantial psychological burden. Although Janus kinase (JAK) inhibitors such as tofacitinib have shown promising efficacy, evidence on their long-term real-world use, particularly in Middle Eastern populations, remains scarce. This study addresses this gap by evaluating extended real-world outcomes of oral tofacitinib in a Saudi Arabian cohort.
methodsThis retrospective cohort study evaluated patients with AA treated with oral tofacitinib at a tertiary care center between 2018 and 2024, providing up to six years of follow-up. Patients who received tofacitinib for at least 12 months were included. Demographic data, disease characteristics, treatment regimens, clinical response, adverse events, and laboratory parameters were extracted from electronic medical records. Associations were analyzed using appropriate statistical tests.
resultsSixteen patients were included, 56.3% female (n = 9), with a mean age of 29.6 ± 9.2 years. Most patients had AA (93.8%, n = 15), and one had alopecia totalis (6.3%, n = 1). An effective response was achieved in 68.8% of patients (n = 11), while 31.3% (n = 5) showed no meaningful response. Hyperlipidemia was the most frequent adverse event (87.5%, n = 14) and was managed conservatively or with lipid-lowering therapy without treatment discontinuation. No serious adverse events or cardiovascular complications were observed. Ongoing side effects (62.5%, n = 10) were significantly associated with treatment response (p = 0.018). Some patients required dose escalation or were switched to alternative JAK inhibitors with favorable outcomes.
conclusionIn this six-year real-world Saudi cohort, oral tofacitinib demonstrated favorable long-term effectiveness in patients with AA. Despite frequent lipid abnormalities, adverse events were manageable with routine monitoring, supporting the feasibility of long-term tofacitinib therapy in carefully selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.